DGAP-News: BB BIOTECH AG
/ Key word(s): Annual Results/Dividend
Media release as of February 19, 2021
Annual report of BB Biotech AG as of December 31, 2020
BB Biotech AG publishes its 2020 annual report
BB Biotech AG published its annual report for fiscal year 2020 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the biotechnology sector, BB Biotech 's positioning, the investment areas covered by its portfolio and the companies it is invested in.
BB Biotech performed well in a volatile market environment. For the full year, total share return was 19.3% in CHF and 18.1% in EUR and the portfolio performance was 24.3% in CHF, and 24.8% in EUR. The consolidated and audited full year 2020 data showed a net gain of CHF 691 mn compared to a net gain of CHF 677 mn for 2019.
As already announced on January 22, 2021, BB Biotech will propose a dividend of CHF 3.60 per share at the upcoming Annual General Meeting, which represents a yield of 5% based on the volume-weighted average price of BB Biotech shares in December 2020. This marks a continuation of the dividend policy of the previous years.
For further information:
|Company:||BB BIOTECH AG|
|Phone:||+41 52 624 08 45|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Mailand, SIX|
|EQS News ID:||1169464|
|End of News||DGAP News Service|